​The Challenge
Conventional antibody–drug conjugates rely on cell-surface antigens that support productive internalization.
Many internalizing targets are also expressed on healthy tissues, limiting selectivity and narrowing the therapeutic window.
Target density and internalization efficiency can vary across tumors.
Our Approach
Develop a proprietary precision-oncology platform that leverages highly tumor-selective biological features underutilized in targeted therapeutic delivery.
Enable more selective, controlled delivery of potent therapeutics.
Expand the range of biological opportunities available for targeted cancer treatment.
Platform Potential. 
​Improved tumor selectivity. Controlled therapeutic activity. Efficient intracellular delivery
Flexible target and payload selection.
​ Development Progress
Protein production and biochemical characterization completed
Early platform feasibility demonstrated
Cellular proof-of-concept studies underway
Our Development Principles
Selectivity: Concentrate therapeutic activity within the disease environment.
Control: Limit potent activity outside the intended site.
Modularity: Support multiple targets, payloads, and oncology indications.
Translation: Prioritize reproducibility, manufacturability, safety, and clinical potential.
Our Goal
Broaden the range of actionable oncology targets.
Advance safer, more selective, and more effective cancer therapies.
​
Conqueror Biopharma is currently operating in stealth mode. Additional scientific and program details remain confidential.

​